NCT00180128

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia(APL)

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Technische Universität Dresden · Academic / Other
• Sex: All
• Age: 16 Years
• Healthy volunteers: Not accepted

Summary

In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine. Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA is performed.

Detailed description

In AIDA 2000 therapy of acute promyelocytic leukemia (APL) is given in a risk-adapted manner. Risk factors are age and white-blood-cell (WBC)-count at diagnosis. Induction therapy is done with ATRA and idarubicin followed by postremission therapy with daunorubicin and mitoxantrone in age adapted dosages. Patients with an high WBC were additionally treated with cytarabine. Finally a two year period of maintenance therapy with 6-mercaptopurine, methotrexate and ATRA is performed.

Conditions

• Leukemia, Promyelocytic, Acute

Interventions

Type	Name	Description
DRUG	all-trans retinoid acid
DRUG	idarubicin
DRUG	mitoxantrone
DRUG	daunorubicin
DRUG	cytarabine

Timeline

• Start date: 2000-01-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2005-09-16
• Last updated: 2011-07-11

Locations

1 site across 1 country: Germany